Litigation Details for Pharmacyclics LLC v. Sandoz Inc. (D. Del. 2018)
✉ Email this page to a colleague
Pharmacyclics LLC v. Sandoz Inc. (D. Del. 2018)
| Docket | ⤷ Sign Up | Date Filed | 2018-02-01 |
| Court | District Court, D. Delaware | Date Terminated | 2021-05-11 |
| Cause | 35:271 Patent Infringement | Assigned To | Colm Felix Connolly |
| Jury Demand | Defendant | Referred To | Christopher J. Burke |
| Parties | TEVA PHARMACEUTICALS USA, INC. | ||
| Patents | 10,004,746; 10,010,507; 10,016,435; 10,106,548; 10,125,140; 10,213,386; 10,294,231; 10,294,232; 7,514,444; 8,008,309; 8,476,284; 8,497,277; 8,697,711; 8,735,403; 8,754,090; 8,754,091; 8,952,015; 8,957,079; 8,999,999; 9,125,889; 9,181,257; 9,296,753; 9,540,382; 9,655,857; 9,713,617; 9,725,455; 9,795,604; 9,801,881; 9,801,883 | ||
| Attorneys | Neal C. Belgam | ||
| Firms | Morris, Nichols, Arsht & Tunnell | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Pharmacyclics LLC v. Sandoz Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Pharmacyclics LLC v. Sandoz Inc. (D. Del. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2018-02-01 | 1 | United States Patent Nos. 8,008,309 (“the ’309 Patent”); 7,514,444 (“the ’444 Patent”); 8,697,711 (“…(“the ’711 Patent”); 8,735,403 (“the ’403 Patent”); 8,957,079 (“the ’079 Patent”); 9,181,257 (“the ’257…’257 Patent”); 8,754,091 (“the ’091 Patent”); 8,497,277 (“the ’277 Patent”); 8,952,015 (“the ’015 Patent…37 PageID #: 2 Patent”); 9,296,753 (“the ’753 Patent”); 9,725,455 (“the ’455 Patent”); 9,540,382 (“the… 1. This action for patent infringement, brought pursuant to the patent laws of the United States | External link to document | |
| 2019-02-14 | 103 | ’548 Patents, and U.S. Patent Nos. 8,999,999 (“the ’999 Patent”); 9,801,881 (“the ’881 Patent”); 9,801,883… 16304 Patent”); 10,125,140 (“the ’140 Patent”); and 10,106,548 (“the ’548 Patent”). Sun has submitted… 1. This action for patent infringement, brought pursuant to the patent laws of the United States… the expiration of the U.S. Patent Nos. 9,296,753 (“the ’753 Patent”) 9,725,455 (“the ’455 Case 1:18…26. This civil action for patent infringement arises under the patent laws of the United States | External link to document | |
| 2019-02-14 | 104 | Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,296,753 B2 ;9,725,455 B1 ;8,999,999 B2 ;9,801,881… 2018 11 May 2021 1:18-cv-00192 835 Patent - Abbreviated New Drug Application(ANDA) Defendant | External link to document | |
| 2019-03-15 | 128 | Answer to Counterclaim | including but not limited to U.S. Patent No. 8,952,015 (“the ’015 Patent”). ANSWER: Denied. …’753 Patent, the ’455 Patent, the ’382 Patent, the ’617 Patent, the ’090 Patent, the ’889 Patent, the…’753 Patent, the ’455 Patent, the ’382 Patent, the ’617 Patent, the ’090 Patent, the ’889 Patent, the…’753 Patent, the ’455 Patent, the ’382 Patent, the ’617 Patent, the ’090 Patent, the ’889 Patent, the…753 Patent, the ’455 Patent, the ’382 Patent, the ’617 Patent, the ’090 Patent, the ’889 Patent, the | External link to document |
| 2019-05-24 | 161 | Patent/Trademark Report to Commissioner of Patents | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,016,435 B2 . (Blumenfeld, … 2018 11 May 2021 1:18-cv-00192 835 Patent - Abbreviated New Drug Application(ANDA) Defendant | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
